

Yuan-Kai Shi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6551898/publications.pdf>

Version: 2024-02-01

51
papers

4,880
citations

279701

23
h-index

182361

51
g-index

52
all docs

52
docs citations

52
times ranked

5710
citing authors

#	ARTICLE	IF	CITATIONS
1	A Prospective, Molecular Epidemiology Study of EGFR Mutations in Asian Patients with Advanced Non-Small-Cell Lung Cancer of Adenocarcinoma Histology (PIONEER). <i>Journal of Thoracic Oncology</i> , 2014, 9, 154-162.	0.5	1,131
2	Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. <i>Lancet Oncology</i> , The, 2016, 17, 577-589.	5.1	950
3	Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial. <i>Lancet Oncology</i> , The, 2013, 14, 953-961.	5.1	389
4	Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2018, 4, 1569.	3.4	388
5	Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial. <i>Journal of Thoracic Oncology</i> , 2019, 14, 867-875.	0.5	260
6	Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001-2020). <i>Journal of Hematology and Oncology</i> , 2020, 13, 143.	6.9	226
7	Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302). <i>British Journal of Cancer</i> , 2018, 118, 654-661.	2.9	192
8	Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial. <i>Lancet Haematology</i> , the, 2019, 6, e12-e19.	2.2	176
9	Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China. <i>Journal of Hematology and Oncology</i> , 2017, 10, 69.	6.9	155
10	Results of PROFILE 1029, a Phase III Comparison of First-Line Crizotinib versus Chemotherapy in East Asian Patients with ALK-Positive Advanced Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1539-1548.	0.5	146
11	Final results of the large-scale multinational trial PROFILE 1005: efficacy and safety of crizotinib in previously treated patients with advanced/metastatic ALK-positive non-small-cell lung cancer. <i>ESMO Open</i> , 2017, 2, e000219.	2.0	87
12	Efficacy, safety, and genetic analysis of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small-cell lung cancer: a phase 2b, multicentre, single-arm, open-label study. <i>Lancet Respiratory Medicine</i> , the, 2021, 9, 829-839.	5.2	66
13	Clinical features and outcomes of diffuse large B-cell lymphoma based on nodal or extranodal primary sites of origin: Analysis of 1,085 WHO classified cases in a single institution in China. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2019, 31, 152-161.	0.7	66
14	Safety, Clinical Activity, and Pharmacokinetics of Alflutinib (AST2818) in Patients With Advanced NSCLC With EGFR T790M Mutation. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1015-1026.	0.5	58
15	Chinese guidelines on the diagnosis and treatment of primary lung cancer (2015 version). <i>Cancer</i> , 2015, 121, 3165-3181.	2.0	47
16	Safety and clinical efficacy of toripalimab, a PD-1 mAb, in patients with advanced or recurrent malignancies in a phase I study. <i>European Journal of Cancer</i> , 2020, 130, 182-192.	1.3	46
17	Efficacy and safety of geptanolimab (GB226) for relapsed or refractory peripheral T cell lymphoma: an open-label phase 2 study (Gxplore-002). <i>Journal of Hematology and Oncology</i> , 2021, 14, 12.	6.9	40
18	Clinical and Testing Protocols for the Analysis of Epidermal Growth Factor Receptor Mutations in East Asian Patients with Non-small Cell Lung Cancer: A Combined Clinical-Molecular Pathological Approach. <i>Journal of Thoracic Oncology</i> , 2011, 6, 1663-1669.	0.5	37

#	ARTICLE	IF	CITATIONS
19	China experts consensus on the diagnosis and treatment of advanced stage primary lung cancer (2016) <i>TJ ETQq1</i> 1,0,784314,348BT /Ove	0.7	31
20	Clinical response to apatinib monotherapy in advanced non-small cell lung cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2018, 14, 264-269.	0.7	31
21	Activity and Safety of Geptanolimab (GB226) for Patients with Unresectable, Recurrent, or Metastatic Alveolar Soft Part Sarcoma: A Phase II, Single-arm Study. <i>Clinical Cancer Research</i> , 2020, 26, 6445-6452.	3.2	30
22	Prognostic Nomogram for Overall Survival in Patients with Diffuse Large B-Cell Lymphoma. <i>Oncologist</i> , 2019, 24, e1251-e1261.	1.9	29
23	Autoantibody profiling identifies predictive biomarkers of response to anti-PD1 therapy in cancer patients. <i>Theranostics</i> , 2020, 10, 6399-6410.	4.6	26
24	High-dose therapy and autologous stem cell transplantation in peripheral T-cell lymphoma: treatment outcome and prognostic factor analysis. <i>International Journal of Hematology</i> , 2014, 99, 69-78.	0.7	21
25	A Prospective Study of Apatinib in Patients with Extensive-Stage Small Cell Lung Cancer After Failure of Two or More Lines of Chemotherapy. <i>Oncologist</i> , 2020, 25, e833-e842.	1.9	19
26	A phase 3 study of rituximab biosimilar HLX01 in patients with diffuse large B-cell lymphoma. <i>Journal of Hematology and Oncology</i> , 2020, 13, 38.	6.9	18
27	Bevacizumab biosimilar LY01008 compared with bevacizumab (Avastin) as first-line treatment for Chinese patients with unresectable, metastatic, or recurrent non-small cell lung cancer: A multicenter, randomized, double-blind, phase III trial. <i>Cancer Communications</i> , 2021, 41, 889-903.	3.7	16
28	Efficacy and safety of rh-endostatin (Endostar) combined with pemetrexed/cisplatin followed by rh-endostatin plus pemetrexed maintenance in non-small cell lung cancer: A retrospective comparison with standard chemotherapy. <i>Thoracic Cancer</i> , 2018, 9, 1354-1360.	0.8	14
29	The changing landscape of anti-lung cancer drug clinical trials in mainland China from 2005 to 2020. <i>The Lancet Regional Health - Western Pacific</i> , 2021, 11, 100151.	1.3	13
30	Molecular profiling of Chinese R-CHOP treated DLBCL patients: Identifying a high-risk subgroup. <i>International Journal of Cancer</i> , 2020, 147, 2611-2620.	2.3	12
31	Circulating tumor cells (CTCs)/circulating tumor endothelial cells (CTECs) and their subtypes in small cell lung cancer: Predictors for response and prognosis. <i>Thoracic Cancer</i> , 2021, 12, 2749-2757.	0.8	12
32	Phase 1/2 study of ceritinib in Chinese patients with advanced anaplastic lymphoma kinase-rearranged non-small cell lung cancer previously treated with crizotinib: Results from ASCEND-6. <i>Lung Cancer</i> , 2020, 150, 240-246.	0.9	10
33	Efficacy and safety of aflutinib (AST2818) in patients with T790M mutation-positive NSCLC: A phase IIb multicenter single-arm study. <i>Journal of Clinical Oncology</i> , 2020, 38, 9602-9602.	0.8	10
34	R-CHOP immunochemotherapy plus surgery is associated with a superior prognosis in Chinese primary intestinal diffuse large B-cell lymphoma. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2020, 16, 385-391.	0.7	9
35	The changing landscape of anti-lymphoma drug clinical trials in mainland China in the past 15 years (2005-2020): A systematic review. <i>The Lancet Regional Health - Western Pacific</i> , 2021, 8, 100097.	1.3	9
36	The prognostic significance of tumor spread through air space in stage I lung adenocarcinoma. <i>Thoracic Cancer</i> , 2022, 13, 997-1005.	0.8	9

